Research programme: cannabinoid-based therapeutics - CannaKids/CURE Pharmaceutical

Drug Profile

Research programme: cannabinoid-based therapeutics - CannaKids/CURE Pharmaceutical

Latest Information Update: 09 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CannaKids; Cure Pharmaceutical
  • Class Cannabinoids
  • Mechanism of Action Cannabinoid receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Unspecified

Most Recent Events

  • 05 Apr 2018 The USPTO issues two US patents (9 044 390 and 9 186 386) to Cure pharmaceuticals for extraction and fractioning of bioactive cannabinoid molecules
  • 18 May 2017 CURE Pharmaceuticals has a patent published by the USPTO entitled "Pharmaceutical Composition with Ionically Crosslinked Polymer Encapsulation of Active Ingredient" which covers CureFilm™ drug delivery technology
  • 06 Mar 2017 CURE Pharmaceutical and CannKids enter research collaboration to develop cannabinoid-based therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top